latest news in companies
Bending Spoons Expands Digital Workspace Holdings with $1.36 Billion Miro Deal
Milan, Thursday, 10 September 2026.
Bending Spoons has agreed to acquire workspace platform Miro for $1.36 billion in cash. Generating $600 million annually, Miro joins Bending Spoons’ portfolio following its recent Airtable acquisition.
Valsoft Enters American Public Health Market with Key Software Acquisition
Montreal, Thursday, 10 September 2026.
Valsoft Corporation has acquired Medicalistics, expanding into U.S. correctional healthcare technology. The deal brings digital health management tools serving over 430,000 patients into Valsoft’s growing software portfolio.
Kiteworks Buys Bonfy.AI to Block Data Leaks in the Age of Artificial Intelligence
San Mateo, Thursday, 10 September 2026.
By acquiring Bonfy.AI, Kiteworks addresses the growing risk of data leaks during real-time movement, marking the cybersecurity firm’s eighth strategic acquisition in under five years.
Healthcare Analytics Pioneer Secures $47 Million for National Expansion
Columbia, Thursday, 10 September 2026.
After saving health plans $975 million without prior institutional backing, digital health platform Vheda Health secured $47 million from Agora to scale its specialized analytics nationwide.
How Defense Deals Are Funding Switzerland's First Advanced Quantum Computer
Zurich, Thursday, 10 September 2026.
A Swiss military procurement agreement is funding the nation’s first IBM Quantum System Two, expanding research in quantum navigation and materials science through ETH Zurich by late 2026.
Estée Lauder Teams Up With Digital Creators to Launch Its Latest Fragrance in New York
New York, Thursday, 10 September 2026.
Ahead of New York Fashion Week, Estée Lauder hosted digital creator Olandria to unveil its new scent, Glimmer, marking a strategic shift toward creator-led marketing for younger consumers.
Why Major Drugmakers Are Overhauling How They Build Complex Medicines
New York, Thursday, 10 September 2026.
Global biopharmaceutical companies are fundamentally restructuring their supply chains, abandoning traditional vendor contracts in favor of long-term strategic partnerships with development and manufacturing organizations. As pipeline development tilts toward complex modalities—such as targeted therapies, peptides, and high-potency active ingredients, which now account for over 40% of new candidates in development—in-house technical demands have surged. To navigate strict regulatory hurdles and capital efficiency demands, drugmakers rely on specialized partners for advanced solutions, ranging from continuous manufacturing to high-containment automation. These integrated alliances are yielding critical results: strategic process optimizations have boosted production yields by over 90% and shortened drug filing timelines to eight months. Furthermore, major market moves, including multi-billion-dollar acquisitions in the peptide manufacturing sector, highlight an aggressive industry-wide shift toward securing reliable, specialized capacity. Strategic alignment and governance are becoming as essential as scientific innovation in bringing modern therapeutics to market.